Steven Shilling
Cardiovascular Disease · Irving, TXNPI 1629077524
Payments from drug & device makers
$324,198in general payments, 2019–2025
Across 166 payments — averaging $1953.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$299K
- Shire North American Group Inc$25K
What the payments were for
- Consulting fees$323,731100%
- Travel & lodging$4670%
General payments by program year
19
20
21
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 154 | $299,478 |
| Shire North American Group Inc | 12 | $24,720 |
How this compares
$324,198 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Irving
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.